home / stock / pbd / pbd news


PBD News and Press, Invesco Global Clean Energy From 01/31/23

Stock Information

Company Name: Invesco Global Clean Energy
Stock Symbol: PBD
Market: NYSE

Menu

PBD PBD Quote PBD Short PBD News PBD Articles PBD Message Board
Get PBD Alerts

News, Short Squeeze, Breakout and More Instantly...

PBD - Invesco Global Clean Energ PBD Trading Signals

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes trading in ...

PBD - Investing In Green Infrastructure: 7 Themes To Watch Out For

Summary In the present time, climate change is progressively inflicting cascading shocks on our environment, economies, and society. Green transportation prioritizes the effective use of energy resources through the creation of energy-efficient modes of transportation and the transforma...

PBD - The Benefits Of Lower Correlations

Summary Correlations across U.S. equity, international equity, and fixed income rose in 2022 as global central banks increased policy rates to reduce consumer demand and curb inflation. International markets may benefit as peak pessimism fades. Energy, Communication Services, and In...

PBD - Protalix BioTherapeutics Issues 2023 Letter to Stockholders

Protalix BioTherapeutics Issues 2023 Letter to Stockholders PR Newswire CARMIEL, Israel , Jan. 3, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commerci...

PBD - Invesco Global Clean Energy ETF declares quarterly distribution of $0.2965

Invesco Global Clean Energy ETF ( NYSEARCA: PBD ) - $0.2965 . Payable Dec 23; for shareholders of record Dec 20; ex-div Dec 19. For further details see: Invesco Global Clean Energy ETF declares quarterly distribution of $0.2965

PBD - Protalix BioTherapeutics to Delist its Common Stock from the Tel Aviv Stock Exchange

Protalix BioTherapeutics to Delist its Common Stock from the Tel Aviv Stock Exchange PR Newswire The Company's Common Stock will continue to trade on the NYSE American CARMIEL, Israel , Dec. 21, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE Am...

PBD - Energy Outlook 2023: The Growth In Renewables, Batteries, CCS And Hydrogen Infrastructure

Summary We expect to see 58 GW growth in the combined wind and solar market in Europe and 32 GW in the US in 2023. Global commercial CCS capacity that is operational or under development is set to grow by 44% this year to 244 million tonnes per annum. Hydrogen is still in its infanc...

PBD - Investment Strategy Monthly Insights, December 2022

Summary The top two mega themes in terms of global net inflows in 2022 were Climate Change-related themes and Big Data. The largest net outflows came from tech-heavy themes, led by Robotics & Automation. 2023 may bring a return to more normal markets driven by economics rather t...

PBD - Carbon Handprint: It's What Firms Don't Do That Counts

Summary As global warming worries approach critical mass, corporate bond investors expect issuers to be part of the solution. At the epicenter of the climate crisis are greenhouse gases (GHG), which all industries emit in one way or another. Most companies strive to shrink their emi...

PBD - Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of a Resubmitted Biologics License Application for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease

Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of a Resubmitted Biologics License Application for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease PR Newswire CARMIEL, Israel and BOSTON ,...

Previous 10 Next 10